JP6050927B2 - 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 - Google Patents
高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 Download PDFInfo
- Publication number
- JP6050927B2 JP6050927B2 JP2010506563A JP2010506563A JP6050927B2 JP 6050927 B2 JP6050927 B2 JP 6050927B2 JP 2010506563 A JP2010506563 A JP 2010506563A JP 2010506563 A JP2010506563 A JP 2010506563A JP 6050927 B2 JP6050927 B2 JP 6050927B2
- Authority
- JP
- Japan
- Prior art keywords
- factor
- protein
- vitamin
- dependent
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 23
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 title description 48
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title description 12
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title description 12
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 94
- 108010076282 Factor IX Proteins 0.000 claims description 92
- 229960004222 factor ix Drugs 0.000 claims description 89
- 125000005629 sialic acid group Chemical group 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 239000003636 conditioned culture medium Substances 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 238000005349 anion exchange Methods 0.000 claims 2
- 238000005342 ion exchange Methods 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 65
- 102000004169 proteins and genes Human genes 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 48
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 239000013598 vector Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- 239000013604 expression vector Substances 0.000 description 15
- 229940031422 benefix Drugs 0.000 description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 13
- 230000004988 N-glycosylation Effects 0.000 description 12
- 229930003448 Vitamin K Natural products 0.000 description 12
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 12
- 235000019168 vitamin K Nutrition 0.000 description 12
- 239000011712 vitamin K Substances 0.000 description 12
- 150000003721 vitamin K derivatives Chemical class 0.000 description 12
- 229940046010 vitamin k Drugs 0.000 description 12
- 108010013113 glutamyl carboxylase Proteins 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 108010056902 Mononine Proteins 0.000 description 10
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 description 10
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 229940090053 mononine Drugs 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 208000031220 Hemophilia Diseases 0.000 description 8
- 208000009292 Hemophilia A Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000006251 gamma-carboxylation Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 4
- 101800004937 Protein C Proteins 0.000 description 4
- 102000017975 Protein C Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 101800001700 Saposin-D Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229940012426 factor x Drugs 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229960000856 protein c Drugs 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010023321 Factor VII Proteins 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 108010066124 Protein S Proteins 0.000 description 3
- 102000029301 Protein S Human genes 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 239000012614 Q-Sepharose Substances 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000019635 sulfation Effects 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- KUTXFBIHPWIDJQ-BTPXSFBUSA-N (1ar,7as)-7a-methyl-1a-[(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enyl]naphtho[2,3-b]oxirene-2,7-dione Chemical compound O=C1C2=CC=CC=C2C(=O)[C@@]2(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@]1(C)O2 KUTXFBIHPWIDJQ-BTPXSFBUSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000021523 carboxylation Effects 0.000 description 2
- 238000006473 carboxylation reaction Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001367049 Autographa Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000255890 Galleria Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241001598112 Rachiplusia ou MNPV Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 102100038182 Vitamin K-dependent gamma-carboxylase Human genes 0.000 description 1
- 101710133062 Vitamin K-dependent gamma-carboxylase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 108091005606 gamma-carboxylated proteins Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
本出願は2007年5月10日に提出した米国仮出願第60/917,271号および2007年4月26日に提出した米国仮出願第60/914,281号への優先権を主張する。両出願は参照によりここに取り込まれる。
きるN−グリカン構造および組成の変化を同定できれば、その結果として臨床的および商業的に優れたr第IX因子製品を合成できるであろう。明らかに、もしも動物におけるよりよい生物学的利用能および/または比較的長い循環半減期を示すr第IX因子分子が合成できれば、この分子を患者へ投与量あたりより少なく投与しなければならないほどに、治療効力はより大きくなる可能性がある。従って、血友病患者の治療のための臨床応用はより安全(投与にはより少ない製品が必要とされる)かつ安価(より多くの投与された製品が回収される)になるであろう。
「薬物動態特性」との語はその通常および慣例の意味を持ち、VKDタンパク質の吸収、分布、代謝および排泄に言及する。本発明による改善された薬物動態特性を得るため、VKDタンパク質の吸収、分布、代謝および排泄の1以上が、通常はヒト血漿中に見出される対応するVKDタンパク質である参照VKDタンパク質に比較して改善される。
形成のような潜在性の有害事象状態にある患者にとっては明らかな利点である。第2に、新しいr第IX因子が患者へ投与されたとき、その患者において著しく多量の第IX因子が長時間循環することとなる。このような状態は、血友病患者の「応需型」または予防的処置のいずれかにおけるより少ない投与を導く。血友病B患者における止血を制御するためのより少ない投与は、患者にとっての明らかな臨床的利点である。
らのプロペプチド領域の除去を促進する。
Manual", 2nd ed (1989); "DNA Cloning", Vol. I and II (D. N Glover ed. 1985); "Oligonucleotide Synthesis" (M. J. Gait ed. 1984); "Nucleic Acid Hybridization" (B. D. Hames and S. J. Higgins eds. 1984); "Transcription and Translation" (B. D. Hames and S. J. Higgins eds. 1984); "Animal Cell Culture" (R. I. Freshney ed. 1986); "Immobilized Cells and Enzymes" (IRL Press, 1986); B. Perbal, "A Practical Guide to Molecular Cloning" (1984); Methods in Enzymology (Academic Press, Inc.)のシリーズ、特に Vol. 154 および 155 (各々、Wu and Grossman, および Wu, eds.,);
"Gene Transfer Vectors for Mammalian Cells" (J. H. Miller and M. P. Calos eds. 1987, Cold Spring Harbor Laboratory); " Immunochemical Methods in Cell and Molecular Biology", Mayer and Walker, eds. (Academic Press, London, 1987); Scopes, "Protein Purification: Principles and Practice", 2nd ed. 1987 (Springer- Verlag, N.Y.); および "Handbook of Experimental Immunology" VoIs I-IV (D. M. Weir および C. C. Blackwell eds 1986)を参照のこと。本背景技術および明細書中に引用された全ての特許、特許出願、および出版物は参照によりここに取り込まれる。
ある実施形態によれば、参照によりここに取り込まれる米国特許出願第2003/0220247号において考察されているように、天然プロペプチド配列をガンマカルボキシラーゼに対するより低いアフィニティーを有するプロペプチド配列に置き換えることにより、γ−カルボキシル化は増加する。有用なプロペプチド配列は、異種性のビタミンK依存性タンパク質の野生型配列またはプロペプチド配列の変化型、あるいはその組み合わせを含む。ビタミンK依存性タンパク質中のプロペプチド配列は、タンパク質のガンマカルボキシル化を導く酵素の認識エレメントである。ビタミンK依存性タンパク質は、高パーセンテージのガンマカルボキシル化された成分を含まない限り完全に機能的ではない。従って、これらのタンパク質の組換え型を作り出す際には、その完全なガンマカルボキシル化を確保するための機構を導入することが重要である。
ここで用いられる「PACE」との語は、対の塩基性アミノ酸変換(または切断)酵素に対する頭字語である。最初にヒト肝細胞株から分離されたPACEは、サブチリシン様エンドペプチダーゼ、すなわちポリペプチドの塩基性残基、例えば−Lys−Arg−、−Arg−Arg、または−Lys−Lys−の切断に特異性を示すプロペプチド切断酵素である。PACEはカルシウムイオンによって刺激され、フッ化フェニルメチルスルホニル(PMSF)によって阻害される。PACE(またはフューリン)をコードするDNA配列は、参照によりここに取り込まれる米国特許第5,460,950号の図1[配列番号1]に示される。PACEと、成熟タンパク質の産生のためにプロセシングを必要とするプロタンパク質との共発現は、成熟タンパク質の高レベルの発現をもたらす。さらに、PACEと、生物学的活性のためにγ−カルボキシル化を必要とするタンパク質との共発現は、真核細胞、好ましくは哺乳類細胞における機能的で生物学的に活性のある成熟タ
ンパク質の増加した収率での発現を可能にする。
ビタミンK依存性エポキシド還元酵素(VKOR)は、これを補助因子とする反応の間にビタミンKがビタミンKエポキシドに変換されることから、ビタミンK依存性タンパク質にとって重要である。ヒト食餌中のビタミンKの量は限られている。それ故に欠乏を防ぐため、ビタミンKエポキシドはVKORによってビタミンKへ逆変換されなければならない。VKOR配列は既知であり入手可能である(例えば受入番号AY521634、Li, et al. (2004) Nature 427: 541-544を参照のこと)。結果としてVKORとの共トランスフェクションは、ビタミンK依存性γ−グルタミルカルボキシラーゼ(VKCG)のようなビタミンK依存性酵素の適切な機能のために十分なビタミンKを供給する。VKCGは、ビタミンK依存性凝固因子のgla−ドメインのγ-カルボキシル化を触媒する。
ビタミンK依存性γ−グルタミルカルボキシラーゼ(VKGC)は、ビタミンK依存性タンパク質の翻訳後修飾に関与するER酵素である。VKGCは、ビタミンK依存性タンパク質中の複数の残基を修飾するため、プロペプチドの約40残基中のグルタミン酸にCO2を取り入れる。3個のカルボキシル化の損失は、ビタミンK依存性凝固因子のようなビタミンK依存性タンパク質の活性を著しく減少させる。ヒトビタミンK依存性γ−グルタミルカルボキシラーゼのcDNA配列は、参照によりここに取り込まれる米国特許第5,268,275号に記載されている。該配列は、米国特許第5,268,275号の配列番号15において提供される。
遺伝的操作による、クローン化された遺伝子、組換えDNA、ベクター、形質転換されたホスト細胞、タンパク質およびタンパク質断片の産生は公知である。例えば、Bell et al.への米国特許第4,761,371号の6列3行から9列65行まで;Clark et al.への米国特許第4,877,729号の4列38行から7列6行まで;Schillingへの米国特許第4,912,038号の3列26行から14列12行まで;およびWallnerへの米国特許第4,879,224号の6列8行から8列59行までを参照のこと。
NA結合部位を含まなければならない。
適切なホスト細胞は原核生物、酵母、あるいは哺乳類細胞および昆虫細胞のような高等真核細胞を含む。多細胞生物由来の細胞は特に組換えビタミンK依存性タンパク質の合成に適したホストであり、哺乳類細胞が特に好ましい。細胞培養によるこのような細胞の増殖は日常的な方法となった(Tissue Culture, Academic Press, Kruse and Patterson, editors (1973))。有用なホスト細胞株の例は、VEROおよびHeLa細胞、チャイニーズハムスター卵巣(CHO)細胞株、ならびにWI138、HEK293、BHK、COS−7、CV、およびMDCK細胞株である。このような細胞のための発現ベクターは通常、複製開始点、発現されるビタミンK依存性タンパク質をコードするDNAの上流に位置し、かつリボソーム結合部位と共にそれと機能的に結合するプロモーター、RNAスプライス部位(イントロンを含むゲノムDNAを使用する場合)、ポリアデニル化部位、および転写終結配列を(必要であれば)含む。好ましい実施形態によれば、発現はチャイニーズハムスター卵巣(CHO)細胞において、参照によりここに取り込まれる米国特許第5,888,809号の発現システムを用いて行なわれる。
クサギンウワバMNPV、Rachiplusia ou MNPV、またはGalleria ou MNPV由来のベクター)のような発現ベクターが、本発明の実施に用いられてよい。一般的にバキュロウィルス発現ベクターは、ポリヘドリン転写開始シグナルからATG開始部位の範囲の位置のポリヘドリン遺伝子中に挿入され、バキュロウィルスポリヘドリンプロモーターによる転写制御下にある、発現される遺伝子を含むバキュロウィルスゲノムを含む。
r第IX因子を含む馴化培地約10Lを得るために、トランスフェクトしたCHO細胞を15Lのバイオリアクター内で12時間、流加産生モードで増殖させた。回収後、不要な細胞および細胞片を除くために馴化培地を浄化し、タンパク質精製の前に濃縮した。タ
ンパク質精製は、カルシウムイオン結合型のr第IX因子を非結合型から分離するために考案された擬似アフィニティーカラムクロマトグラフィー法を用いて行なった(Yan 1991、米国特許第4,981,952号)。
血友病治療のための高度にシアル化されたr第IX因子製剤を得るため、細胞培養法により得られた馴化培地をタンパク質精製に供し、それにより第IX因子のカルボキシル化された形から完全にガンマ−カルボキシル化された形を分離するため、擬似アフィニティー条件下で1以上のクロマトグラフィー工程が行なわれる(Yan 1991、米国特許第4,981,952号)。N−グリカンあたり3以上のシアル酸残基を持つタンパク質を多量(相対パーセンテージ)に含む画分を得るため、第IX因子の完全にガンマ−カルボキシル化された形をカラムクロマトグラフィーによってさらに分画した(実施例1)。3以上のシアル酸残基を持つタンパク質を妥当なパーセンテージ有するr第IX因子製剤を得
るため、基本的に全ての画分がプールされてよい。N−グリカンあたり3以上のシアル酸残基を持つタンパク質を最大パーセンテージ有するr第IX因子製剤を得るため、カラムから後期に溶出される画分がプールされてよい。一般に、所定の製剤中のシアル酸含量についてのr第IX因子の組成は、表2に例証される所与の標的範囲を達成するために調節されてよい。
生物学的利用能のin vivo分析のための第IX因子の独特の4ロット(ロット1〜4)を得るため、図1に示す画分をプールすることにより組換え第IX因子製剤を得た。表3に示すように、産生されるr第IX因子のロットはグリカンあたり3以上の(3+)シアル酸残基を含んだN−グリカンのパーセンテージに関して異なる。
Claims (3)
- 組換え第IX因子を分離する方法であって;
組換え第IX因子を含む馴化培地を準備すること;および
組換え第IX因子分子中3以上のシアル酸残基を持つN−結合型オリゴ糖のパーセンテージが少なくとも62%である、組換え第IX因子の画分を、カルシウム存在下で1以上のカラムクロマトグラフィー工程により馴化培地より分離すること、
を含み、前記1以上のカラムクロマトグラフィー工程は、カルシウム存在下でアニオン交換カラムを用いるイオン交換クロマトグラフィーである、方法。 - 前記アニオン交換カラムが、イオン交換基として第4級アンモニウム基を有する、請求項1に記載の方法。
- 前記第IX因子が完全にガンマ−カルボキシル化されている、請求項1または2に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91428107P | 2007-04-26 | 2007-04-26 | |
US60/914,281 | 2007-04-26 | ||
US91727107P | 2007-05-10 | 2007-05-10 | |
US60/917,271 | 2007-05-10 | ||
PCT/US2008/061822 WO2008134665A1 (en) | 2007-04-26 | 2008-04-28 | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014246477A Division JP6223319B2 (ja) | 2007-04-26 | 2014-12-05 | 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010525085A JP2010525085A (ja) | 2010-07-22 |
JP6050927B2 true JP6050927B2 (ja) | 2016-12-21 |
Family
ID=39926119
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010506563A Active JP6050927B2 (ja) | 2007-04-26 | 2008-04-28 | 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 |
JP2014246477A Active JP6223319B2 (ja) | 2007-04-26 | 2014-12-05 | 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014246477A Active JP6223319B2 (ja) | 2007-04-26 | 2014-12-05 | 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 |
Country Status (6)
Country | Link |
---|---|
US (3) | US20100081187A1 (ja) |
EP (2) | EP2139499A4 (ja) |
JP (2) | JP6050927B2 (ja) |
AU (1) | AU2008245524A1 (ja) |
CA (2) | CA3090908A1 (ja) |
WO (1) | WO2008134665A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101982455B1 (ko) * | 2016-02-12 | 2019-05-27 | 오므론 가부시키가이샤 | 제어 스위치 기구, 트리거 스위치 및 전동 공구 |
KR102087349B1 (ko) * | 2013-08-09 | 2020-04-24 | 애플 인크. | 전자 디바이스용 촉각 스위치 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
AU2010290077C1 (en) * | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
AU2012304763A1 (en) | 2011-09-06 | 2014-03-06 | Medimmune Llc | Methods for processing coagulation factors |
EP3549953A1 (en) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
BR112015015182B1 (pt) | 2012-12-24 | 2023-12-26 | Coagulant Therapeutics Corporation | Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos |
WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
DE3101752A1 (de) * | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen" |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4599308A (en) | 1981-10-06 | 1986-07-08 | Hamer Dean H | Protein from SV40 recombinants |
DE3380848D1 (en) | 1982-08-04 | 1989-12-21 | Nat Res Dev | Molecular cloning of the gene for human anti-haemophilic factor ix |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
FR2564106B1 (fr) | 1984-05-09 | 1988-04-22 | Transgene Sa | Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix. |
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4745057A (en) | 1984-05-18 | 1988-05-17 | Eli Lilly And Company | Method, vectors and transformants for high expression of heterologous polypeptides in yeast |
JPH082307B2 (ja) | 1984-05-22 | 1996-01-17 | トランスジ−ン ソシエテ アノニム | 第▲ix▼因子の製造方法 |
US4912038A (en) | 1984-12-11 | 1990-03-27 | California Biotechnology Inc. | Recombinant DNA sequence encoding alveolar surfactant protein |
US4879224A (en) | 1985-01-10 | 1989-11-07 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides |
US4761371A (en) | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
FR2600334B1 (fr) | 1986-06-23 | 1989-05-12 | Transgene Sa | Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation |
US4877729A (en) | 1986-07-14 | 1989-10-31 | Genetics Institute, Inc. | Recombinant DNA encoding novel family of primate hematopoietic growth factors |
US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
FR2638643B1 (fr) | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
ATE158816T1 (de) | 1990-11-26 | 1997-10-15 | Genetics Inst | Expression von pace in wirtszellen und verfahren zu dessen verwendung |
US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
US5714583A (en) * | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
IL130964A0 (en) * | 1997-01-16 | 2001-01-28 | Cytel Corp | Practical in vitro sialylation of recombinant glycoproteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
DE60115613T2 (de) * | 2000-03-22 | 2006-08-24 | Octagene Gmbh | Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien |
DE60137950D1 (de) * | 2000-10-02 | 2009-04-23 | Novo Nordisk Healthcare Ag | Verfahren zur herstellung vitamin-k-abhängiger proteine |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
AU2004296860B2 (en) * | 2003-12-03 | 2010-04-22 | Novo Nordisk A/S | Glycopegylated factor IX |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
EP2975135A1 (en) * | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
PT1969127E (pt) * | 2005-12-21 | 2014-09-23 | Univ North Carolina | Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes |
DK2101821T3 (da) * | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
-
2008
- 2008-04-28 EP EP08747060A patent/EP2139499A4/en not_active Withdrawn
- 2008-04-28 WO PCT/US2008/061822 patent/WO2008134665A1/en active Application Filing
- 2008-04-28 CA CA3090908A patent/CA3090908A1/en not_active Abandoned
- 2008-04-28 JP JP2010506563A patent/JP6050927B2/ja active Active
- 2008-04-28 US US12/597,456 patent/US20100081187A1/en not_active Abandoned
- 2008-04-28 CA CA2683423A patent/CA2683423C/en active Active
- 2008-04-28 EP EP12170422A patent/EP2517714A1/en not_active Withdrawn
- 2008-04-28 AU AU2008245524A patent/AU2008245524A1/en not_active Abandoned
-
2014
- 2014-12-05 JP JP2014246477A patent/JP6223319B2/ja active Active
-
2015
- 2015-09-21 US US14/860,042 patent/US20160244738A1/en not_active Abandoned
-
2021
- 2021-12-10 US US17/548,124 patent/US20230272360A1/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102087349B1 (ko) * | 2013-08-09 | 2020-04-24 | 애플 인크. | 전자 디바이스용 촉각 스위치 |
KR101982455B1 (ko) * | 2016-02-12 | 2019-05-27 | 오므론 가부시키가이샤 | 제어 스위치 기구, 트리거 스위치 및 전동 공구 |
Also Published As
Publication number | Publication date |
---|---|
JP6223319B2 (ja) | 2017-11-01 |
AU2008245524A1 (en) | 2008-11-06 |
JP2015052016A (ja) | 2015-03-19 |
CA2683423A1 (en) | 2008-11-06 |
CA2683423C (en) | 2020-10-27 |
US20230272360A1 (en) | 2023-08-31 |
EP2139499A4 (en) | 2010-05-05 |
CA3090908A1 (en) | 2008-11-06 |
EP2517714A1 (en) | 2012-10-31 |
US20100081187A1 (en) | 2010-04-01 |
WO2008134665A8 (en) | 2009-09-03 |
EP2139499A1 (en) | 2010-01-06 |
US20160244738A1 (en) | 2016-08-25 |
WO2008134665A1 (en) | 2008-11-06 |
JP2010525085A (ja) | 2010-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6223319B2 (ja) | 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 | |
US20230287471A1 (en) | Method of producing biologically active vitamin k dependent proteins by recombinant methods | |
JP5613876B2 (ja) | 延長された半減期を備えるヒト第ix因子変異体 | |
AU2016238889B2 (en) | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same | |
US20190264188A1 (en) | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same | |
AU2014202989B2 (en) | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same | |
EP2494040B1 (en) | Method of producing recombinant vitamin k dependent proteins | |
AU2013211534B2 (en) | Method of producing biologically active vitamin K dependent proteins by recombinant methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130305 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130522 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140403 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140507 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141205 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150123 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160506 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160804 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6050927 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313114 Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |